Your browser doesn't support javascript.
loading
Quarter-Century PET/Computed Tomography Transformation of Oncology: Hepatobiliary and Pancreatic Cancer.
Kandathil, Asha; Subramaniam, Rathan.
Affiliation
  • Kandathil A; Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: Asha.Kandathil@utsouthwestern.edu.
  • Subramaniam R; Faculty of Medicine, Nursing, Midwifery and Health Sciences, University of Notre Dame Australia, Sydney, Australia; Department of Radiology, Duke University, Durham, NC, USA; Department of Medicine, University of Otago Medical School, Dunedin, New Zealand.
PET Clin ; 19(2): 163-175, 2024 Apr.
Article in En | MEDLINE | ID: mdl-38212214
ABSTRACT
[18F] Fluorodeoxyglucose (18F-FDG) PET/CT can improve the staging accuracy and clinical management of patients with hepatobiliary and pancreatic cancers, by detection of unsuspected metastases. 18F-FDG PET/CT metabolic parameters are valuable in predicting treatment response and survival. Metabolic response on 18F-FDG PET/CT can predict preoperative pathologic response to neoadjuvant therapy in patients with pancreatic cancer and determine prognosis. Several novel non-FDG tracers, such as 68Ga prostate-specific membrane antigen (PSMA) and 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT, show promise for imaging hepatobiliary and pancreatic cancers with potential for radioligand therapy.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Positron Emission Tomography Computed Tomography Limits: Humans / Male Language: En Journal: PET Clin Year: 2024 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Positron Emission Tomography Computed Tomography Limits: Humans / Male Language: En Journal: PET Clin Year: 2024 Type: Article